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17-Estradiol attenuates intimal hyperplasia and
macrophage accumulation with a reduction in
monocyte chemoattractant protein 1 expression in
a vein graft model
Masaaki Ryomoto, MD,a Randal A. Wolff, PhD,b Jeffrey J. Tomas, BS,b Takashi Miyamoto, MD,a and
John R. Hoch, MD,b Madison, Wis
Objective: Autogenous vein grafts are commonly used for arterial reconstructive procedures. Their success is limited by the
development of intimal hyperplasia, a fibroproliferative disease that predisposes the grafts to occlusive stenosis. Our goal
was to assess whether 17-estradiol (E2) inhibits vein graft intimal hyperplasia coincident with a reduction in monocyte
chemoattractant protein 1 (MCP-1) expression and macrophage accumulation.
Method: Male Lewis rats were implanted with time-release pellets that contained 0.5 mg E2 (E5 group) or placebo (PL
group). Epigastric vein to common femoral artery interposition grafts were harvested at 2, 4, 8, and 12 weeks after
surgery. We assessed macrophage/monocytes numbers, proliferating cell nuclear antigen, MCP-1, and transforming
growth factor-1 with use of immunohistochemistry. MCP-1 message expression was quantified by real-time polymerase
chain reaction.
Results: The time-release pellets raised the serum E2 level to greater than 250 pg/mL on the day of surgery. Serum E2 level
declined to 43  13 pg/mL by 4 weeks and to baseline by 6 weeks. We found that the neointimal area ratio was reduced
significantly in the E5 group at 2 and 4 weeks (45%, P < .05, and 68%, P < 0.05, respectively) relative to that in the PL
group. The number of proliferating cells was reduced in the E5 group. There was a significant attenuation of MCP-1
expression and of the number of macrophages accumulating in the graft with E2 treatment. Furthermore, MCP-1
messenger ribonucleic acid expression was also significantly attenuated in the E5 group at 4 weeks when compared to the
PL group. There was no significant difference between the two groups in the expression of transforming growth
factor-1.
Conclusions: E2 treatment reduces vein-graft intimal hyperplasia coincident with a reduction in MCP-1 expression,
macrophage accumulation, and cell proliferation. (J Vasc Surg 2002;36:613-21.)
It is a well-established procedure to use autogenous
vein for peripheral arterial reconstruction rather than pros-
thetic conduits because of the resulting higher patency
rate.1 However, during the first 5 years, the primary autog-
enous vein-graft patency rate for infrainguinal arterial re-
construction has been reported as 62% to 72%.1-4 Vein graft
patency is limited by the development of intimal hyperpla-
sia (IH). Graft stenoses commonly occur at the perianasto-
motic region, where additional injury to the endothelial cell
lining by the anastomotic procedure may be an important
stimulus to an abnormal wound healing response. Central
to wound healing is the macrophage, whose cytokines can
influence monocyte chemotaxis, induction of smooth mus-
cle cell proliferation and migration, and extracellular matrix
production. Endothelial cell and vascular smooth muscle
cell (VSMC) injury may stimulate the release of monocyte
chemoattractant protein 1 (MCP-1).5 MCP-1 is one of the
pivotal chemokines in the vessel wall, and release of this
chemokine causes macrophages to migrate and accumulate
at anastomotic sites. We previously described MCP-1 ex-
pression and subsequent macrophage accumulation coinci-
dent with the development of rat vein graft IH.6
Epidemiologic data suggest that the incidence of car-
diovascular diseases is lower in premenopausal women or
postmenopausal women receiving estrogen replacement
therapy, than in men or postmenopausal women not taking
supplemental estrogen.7 In a clinical setting, it has been
reported that pretreatment with 17-estradiol (E2) can
limit leukocyte activation in men after elective coronary
artery bypass graft surgery.8 The mechanism of estrogen’s
cardioprotective effects is unknown. Pervin et al9 reported
that treatment with E2 resulted in a reduction in aortic
atherosclerosis in rats fed a high cholesterol diet. The
investigators attributed the reduction in atherosclerosis to
reduced expression of MCP-1.9 Although E2 treatment can
reduce atherosclerosis and IH in an aortic allograft model10
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and in arterial balloon injury models,11-13 no successful
results have been reported in an in vivo vein graft model.
In the present study, we demonstrate that estradiol
treatment can reduce vein graft IH coincident with a reduc-
tion in MCP-1 expression and macrophage migration and
accumulation.
METHODS
Treatment, vein grafting, and harvest. The statisti-
cal experimental design was completely randomized. Sub-
ject animals received randomized treatment and time as-
signments by using computer-generated random numbers.
This method ensures that biases between experimental
groups will, on average, be zero. Two days before surgery,
male Lewis rats (weight, 350-450 g) were implanted sub-
cutaneously with time-release pellets (Innovative Research
of America, Sarasota, Fla) containing 0.5 mg of E2 (E5
group) or placebo (PL group).. Epigastric vein to common
femoral artery interposition grafts were placed via aseptic
microsurgical techniques as described previously.14 In
brief, each animal was anesthetized intraperitoneally with
ketamine and xylazine, and the epigastric vein was dissected
from the surrounding tissue. An 8-mm segment of relaxed
epigastric vein was excised, reversed, and interposed into a
3-mm arterial defect. Each anastomosis was completed
with 8 to 10 interrupted sutures of 10-0 nylon. After a
30-minute total ischemic time, hemostasis was restored,
patency was confirmed, and the wound was irrigated and
closed. The animal was observed closely until recovery.
Provision of animal care complied with the Principles of
Laboratory Animal Care (formulated by the National So-
ciety for Medical Research) and the Guide for the Care and
Use of Laboratory Animals. Procedures were approved by
the Research Animal Resources Center at the University of
Wisconsin-Madison.
Harvest time points in this study were 2, 4, 8, and 12
weeks. For quantitative analysis of neointimal area ratio,
hematoxylin and eosin stains of 5 to 10 grafts from each
treatment (E5 or PL) at each time point were examined.
Sections from these grafts were also used for immunohis-
tochemical analysis of ED1, proliferating cell nuclear anti-
gen (PCNA), MCP-1, and transforming growth factor-1
(TGF-1) (n  5 to 8 at each time point for each treat-
ment). For quantitative measurement of MCP-1 messenger
ribonucleic acid (mRNA), n 5 to 6 at each time point for
each treatment. For analysis of mortality risk and to deter-
mine risk of graft failure with E5 treatment vs PL treatment,
animals that were operated on to place grafts for histologic/
immunohistochemistry and mRNA analyses were grouped
together with those operated on in pilot studies: n 74 for
surgeries using animals treated with estrogen and n  57
for surgeries using animals treated with placebo.
Enzyme-linked immunosorbent assay (ELISA) for
estradiol. Blood was taken from rats’ tail veins at the time
of implantation of the pellets, at surgery, once each week
after surgery, and at harvest for the analysis of the blood
serum E2 level. The samples were centrifuged, and the
serum was stored at 20° C until analysis. Serum E2 level
was measured with use of an ELISA kit (YJ Bioproducts,
Rancho Cordova, Calif) per manufacturer’s instructions,
except that 96 half-well plates were used and reagents were
diluted 1:1 in PBSGHT, which consists of gelatin (1 g/L),
hemin (5 mg/L), and 0.05% Tween in 1 phosphate
buffered saline (PBS). TMB (Kirkegaard & Perry Labora-
tories) was used for color development. Plates were read at
450 nm.
Histologic examination. Vein specimens and other
tissues were fixed in 10% formalin overnight at 4° C and
embedded in paraffin as described previously.14 The prox-
imal regions of vein grafts (0 to 3 mm from proximal
anastomotic site) historically displays the most IH. This
region was sectioned (5 m) at intervals as described pre-
viously; the results reported for each graft are an average of
measurements from these sections.6
Immunohistochemistry. Histochemistry and immu-
nohistochemistry were performed according to previously
published methods with modifications.14 Primary antibod-
ies used were against TGF-1 (27235.1; R&D Systems,
Minneapolis, Minn), monocytes and macrophages
(ED1; Serotec, Raleigh, NC), MCP-1 (Peprotec, Rocky
Hill, NJ), and PCNA (PC10; Sigma, St Louis, Mo). A
control primary antibody was used to assure that the
staining observed was not due to nonspecific interac-
tions. Detection of the primary antibody and color de-
velopment was performed by using the Universal DAKO
LSAB 2 Kit, Peroxidase for use on RAT Specimens
(DAKO, Carpinteria, Calif) and DAKO Liquid DAB
Large Volume Substrate-Chromogen System according
to instructions.
Reverse transcription–quantitative polymerase
chain reaction (PCR). The graft was homogenized for
approximately 15 seconds in 0.4 mL of ice cold Trizol
(Invitrogen, Carlsbad, Calif). The mRNA was then ex-
tracted from the Trizol and reverse-transcribed to comple-
mentary deoxyribonucleic acid (cDNA).6,15 Yields of
cDNA were quantified by use of fluorescence spectrometry,
and samples were diluted to 20 ng/L. For quantitative
PCR, we pipetted two standard curves (MCP-1 and the
housekeeping gene hypoxanthine phosphoribosyltrans-
ferase, HPRT). Four reactions of each sample (using 1, 1,
2, and 2 L of sample) were run for each primer set
(MCP-1 and HPRT) in the same run on the Rotor-Gene
2000 (Corbett Research, Australia) as the standard curves.
Cycle threshold was used to determine copies of MCP-1
per copies of HPRT. Comparing the results from reactions
using 1 L of sample to the reactions that used 2 L of
sample confirmed that the measurements were quantita-
tive. The four estimates of MCP-1 copies per copy of
HPRT were then averaged to give the result for each
sample. Primers were designed to include a spice site in the
amplicons as a control for the presence of genomic DNA.
Computerized image analysis and statistics. Images
of vein graft cross-sections were captured with use of a
Nikon microscope and Pixera color camera (Kodak, Roch-
ester, NY). Various morphometric parameters such as total
and neointimal areas and areas of positive immunostaining
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were measured by using image analysis MetaMorph soft-
ware (Universal Imaging, Downington, Pa).6,14,15 Neoin-
timal area ratio (neointimal area/total area), immunohisto-
chemical positively staining area ratio (area stained/total
area), and message quantification were analyzed by analysis
of variance (ANOVA) with Fisher protected least signifi-
cant differences that compared changes over time within a
treatment group, differences between groups, and interac-
tions between time and groups. Specific time points were
compared with pair-wise comparisons within the ANOVA.
Data were transformed using an arcsine square-root trans-
formation (neointimal area ratio and immunohistochemi-
cal positively staining area ratio) or log transformation
(message quantification) to better meet the assumptions of
ANOVA. In a second analysis, the Spearman correlation
coefficients were calculated for the immunohistochemical
positively staining area ratio vs the E2 serum level at harvest
and for the MCP-1 message quantification vs the E2 serum
level at harvest.
RESULTS
Animals and grafting
Overall vein graft patency rate was 90%. When we
applied “proportional hazards model for grouped data,”16
we did not observe a significant difference between the E5
and PL animals for these combined outcomes: graft pa-
tency, occlusion, or thrombosis; P  .1238. However, the
risk ratio for graft patency, occlusion, or thrombosis in the
E5 group compared to the PL group was 5.3, indicating a
higher risk for graft failure in the animals receiving estra-
diol. Kaplan-Meier survival curves (death) followed by log-
rank test yielded P  .5248, indicating no statistically
significant difference in rat survival between the two groups.
Significant body-weight loss was observed in the E5 group, a
maximal difference of 11.5% compared to the PL group
occurred at 1 week after surgery. This trend continued in the
latter weeks. Although animals in both groups gained weight,
those in the E5 group were not able to reach their presurgical
weight, whereas those in the PL group did eventually exceed
their presurgical average weight.
Serum 17-estradiol level
There was no difference in serum E2 levels between the
two groups before implantation of the E2 time-release
pellet. Once E2 pellets were implanted, E2 levels increased
to greater than 250 pg/mL on the day of surgery, which
was 2 days after pellet implantation (Fig 1). E2 levels started
decreasing after 2 days, dropping down to 175  31.4
pg/mL at 2 weeks and 43.0 13.1 pg/mL at 4 weeks. E2
levels returned to pretreatment levels by 6 weeks. No
elevation of E2 levels above baseline was observed in the PL
group (data not shown).
Fig 1. Serum estradiol levels increased significantly in the E5 group. On the day of surgery, 2 days after implantation
of a time-release E2 pellet, E2 levels reached over 250 pg/mL. Although this high E2 level was maintained for 1 week
after surgery, it gradually decreased starting at 2 weeks after surgery and eventually returned to the pre-treatment level
at 6 weeks after surgery. *P .05, E5 group vs PL group. Pre, 2 days prior to surgery and the day of pellet implantation;
surg, day of surgery; POD, postoperative day.
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Intimal hyperplasia was reduced with 17-estradiol
treatment
Cross-sections stained with hematoxylin and eosin re-
vealed that an eccentric neointimal formation consisting of
unorganized cells was produced inside the internal elastic
lamina (IEL). The greatest inflammatory cell infiltration
was observed in 2 week-grafts in both the PL and E5
groups (Fig 2). Neointimal area ratio (NR) was calculated
as the neointimal area over total graft area, and is presented
in Fig 3. NR was increased with graft age in both groups
and was reduced significantly at 2 and 4 weeks after surgery
in the E5 group compared to the PL group (2 weeks—
E5  6.9  1.7%, PL  12.6  1.5%; P  .05. 4 weeks—
E5 8.5 2.0%, PL 26.7 7.4%; P .05). There were,
however, no significant differences at 8 and 12 weeks,
which is when serum E2 returned to pre-treatment levels.
Immunohistochemistry
ED1 (monocytes/macrophages). At 2 weeks, trans-
mural macrophage infiltrations in the grafts were observed
as well as accumulation along the IEL. In the E5 group, less
macrophage accumulation in the IEL was observed com-
pared to PL group, which had many macrophages along the
IEL as well as in the media/adventitia (Fig 4). A quantita-
tive analysis was performed of the ED1 area ratio, which
was calculated by ED1 positive area over total area (Fig 5,
A). ED1 area reached a maximum at 4 weeks after surgery
in the PL group. It is important to note that in the E5
Fig 2. Neointimal formation and cell infiltration to the graft was reduced in the E5 group. More neointimal formation
consisting of unorganized cells was observed in the PL group than in the E5 group at 2 and 4 weeks after surgery.
Further, severe cell infiltration to the graft was seen only in the PL group at 2 weeks. At 8 and 12 weeks, which was after
serum E2 levels returned to normal in the E5 group, no differences could be seen between the two groups. L, Lumen;
M, media/adventitia; N, neointima. Arrow heads indicate the internal elastic lamina. Magnification, 400.
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group, ED1 staining was significantly reduced compared to
the PL group at 2 and 4 weeks by 73.1% and 88.3%,
respectively. ED1 staining peaked in the E5 group at 8
weeks, after serum estradiol levels had returned to baseline
(Fig 5, A). There was no significant difference between the
two groups at 8 and 12 weeks. When time was removed as
a factor, the ED1 area ratio correlated inversely with the
blood serum E2 level at graft harvest (r  0.46, P 
.0007).
Proliferating cell nuclear antigen. In the E5 group,
many fewer PCNA-positive cells were observed compared
to the PL group, which had many positive cells in the media
and adventitia (Fig 4). The ratio of proliferating cell-posi-
tive area was significantly reduced in the E5 group vs the PL
group at 2 and 4 weeks after surgery. PCNA staining
peaked in the E5 group at 8 weeks, after serum estradiol
levels had returned to baseline (Fig 5, B). There was no
significant difference between groups at 8 and 12 weeks.
When time was removed as a factor, the PCNA area ratio
was correlated inversely with the blood serum E2 level at
graft harvest (r  0.59, P  .0001).
Monocyte chemoattractant protein 1. Less MCP-1
positive stain was detected in the E5 group than in the PL
group (Fig 4). The MCP-1–positive cells in the PL group
were observed either in media or in neointima, so that these
cells were likely smooth muscle cells/myofibroblasts, endo-
thelium cells, and macrophages, which are known to be
major sources of MCP-1. In this quantitative analysis,
MCP-1 expression reached a maximum at 2 weeks after
surgery and then gradually decreased in the PL group.
MCP-1 expression was reduced significantly at 2 and 4
weeks in the E5 group compared to the PL group, by 95.6%
and 75.7%, respectively (Fig 5, C). When time was removed
as a factor, the MCP-1 area ratio was inversely correlated to
the serum E2 level at graft harvest (r0.43, P .0026).
Transforming growth factor-1. TGF-1–positive
stain was seen in the endothelial cells and media and adven-
titia in both the E5 and PL groups (Fig 4). Quantitative
analysis showed no significant difference between the two
groups at any time points (Fig 5, D). TGF-1 was highest
at the earliest time point examined (2 weeks) and then
showed a trend toward reduced expression with time.
When time was removed as a factor and the TGF-1 area
ratio was compared to the serum E2 level at graft harvest,
r  0.22 and P  .14 (ie, the relationship did not reach
statistical significance).
Quantitative polymerase chain reaction
Message analysis with quantitative PCR showed that
MCP-1 message expression was attenuated at 2 and 4
weeks after surgery in the E5 group compared to the PL
group by 43.0% and 33.1%, respectively. Although
ANOVA indicated that the attenuation was significant at 4
weeks (P  .015), the attenuation at 2 weeks was not
statistically significant (P .48). No attenuation of MCP-1
message expression was observed at 8 weeks after surgery in
the E5 group compared to the PL group after serum E2
levels returned to baseline in the E5 group (Fig 6). When
time was removed as a factor and the MCP-1 message
expression was compared to the serum E2 level at graft
harvest, r0.18 and P .32 (ie, the relationship did not
reach statistical significance). The lack of correlation is
consistent with ANOVA results at 2 weeks (ie, even though
serum E2 levels were high at the 2-week time point there
was not a statistically significant reduction in MCP-1 mes-
sage expression).
Fig 3. Neointimal area was significantly reduced in the E5 group. Neointimal area ratio was calculated as neointimal
area over total area. At 2 and 4 weeks after surgery, neointimal area ratio was significantly reduced in the E5 group vs
the PL group. On the other hand, there were no significant differences between the two groups at 8 and 12 weeks when
serum E2 returned to pretreatment levels. *P  .05, E5 group vs the PL group.
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DISCUSSION
Leukocytes, macrophages, and their cytokine products
are involved in the development of neointimal hyperplasia.
We have reported that rats treated with L-Cl2MBP, which
depletes monocytes and macrophages, demonstrate signif-
icantly reduced IH at 7 and 14 days after vein grafting.17
Saito and colleagues10 have stated that both macrophage
accumulation and IH were significantly reduced in rat
aortic allografts among animals receiving E2 treatment.
Thus, we hypothesized that E2 treatment might inhibit
vein graft IH coincident with a reduction of MCP-1 expres-
sion and accumulation of macrophages within the graft.
We targeted an E2 level between 150 and 200 pg/mL
because E2 levels of 152  24.9 pg/mL
10 or near 200
pg/mL13 have been reported to reduce IH in rat aortic
allografts and in rat arteries following balloon injury, re-
spectively. We found that the subcutaneous pellets resulted
in an E2 level near 250 pg/mL at the day of surgery. The
time-release pellets, however, kept the E2 level in our
planned therapeutic range for only 3 weeks. IH was re-
duced significantly at 2 and 4 weeks, under the influence of
therapeutic or near-therapeutic levels of E2. At 6 weeks
after surgery, blood serum E2 levels did not differ signifi-
cantly from pretreatment levels. This low level of E2 nega-
Fig 4. Accumulation of macrophage/monocytes and proliferating cells, and expression of MCP-1 were attenuated at
2 weeks after surgery in the E5 group. Macrophages, indicated as ED1 positive cells, accumulated to the internal elastic
lamina in the E5 group. Much macrophage accumulation was shown along the internal elastic lamina as well as in the
media in the PL group. Many proliferating cells, indicated as PCNA positive cells, were observed in media in the PL
group compared to the E5 group. MCP-1 was much higher in the neointima and media in the PL group compared to
the E5 group. Endothelium and media had much TGF-1 positive stain in both groups. All photomicrographs at400
magnification except ED1 stain, which is shown at 100.
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tively influenced our results at the 8- and 12-week time-
points when intimal areas were similar between the E5 and
PL groups. It is of interest that the difference in neointimal
ratio established at 2 and 4 weeks was lost at 8 and 12
weeks, implying that a short treatment with E2 at the time
of vein grafting would not be clinically effective.
E2 treatment resulting in inhibition of postinjury neo-
intimal hyperplasia in arterial models has been well de-
scribed.10-13,18 To our knowledge, prior to our present
work, only one report exists in the literature that examines
the effects of E2 in an in vivo vein graft model of IH.
Calcagno and colleagues19 reported that E2 treatment (se-
rum level, 600 pg/mL) was not effective in inhibiting
intimal hyperplasia in a rabbit vein graft model. They
reported that one graft thrombosed immediately as the
result of a technical problem, whereas 7 of 12 grafts were
found to occlude when harvested at 3 weeks in the E2-
treated group. E2 did not significantly reduce IH in their
limited study. In our study, the neointimal ratio was re-
duced significantly in the E5 group compared to the PL
group: by 24.6% at 2 weeks and 33% at 4 weeks, with a
slight increased risk of occlusion. Gerstman and col-
Fig 5. Number of macrophage/monocytes and proliferating cells accumulating to the graft, and expression of MCP-1
were significantly attenuated at 2 and 4 weeks after surgery in the E5 group. Quantitative analysis of images of
immunohistochemically stained vein graft cross-sections is presented. A, ED1 positive area ratio was significantly
reduced in the E5 group compared to the PL group at 2 and 4 weeks. ED1 accumulation reached a maximum at 4 weeks
in the PL group. B, PCNA stain revealed a significant difference of positive area at 2 and 4 weeks between the two
groups. PCNA positive cell area ratio also reached a maximum at 4 weeks in the PL group. C, MCP-1 expression was
significantly inhibited in the E5 group at 2 and 4 weeks after surgery. In the PL group, the peak MCP-1 expression was
observed at 2 weeks and later decreased gradually. D, TGF-1 stain did not reveal significant differences at any time
points. *P  .05, **P  .01; E5 group vs PL group.
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leagues20 reported an increased risk of deep vein thrombo-
sis related directly to the dose of estrogen in humans.
Perhaps the high incidence of thrombus generation at an
E2 serum level of 600 pg/mL reported by Calcagno and
colleagues overwhelmed any beneficial effects of estrogen
treatment on IH in patent grafts and contributed to the
observed graft failures.
MCP-1, which is one of the pivotal chemokines in-
volved in the inflammatory system, is known to cause
macrophages to migrate and accumulate. Macrophages are
capable of secreting numerous growth factors, which may
influence the development of IH. Once endothelium or
VSMCs are injured, MCP-1 is secreted by these cells.6
VSMCs in our epigastric vein femoral artery interposition
graft model undergo necrosis and apoptosis between 1 and
10 days after surgery.21,22 Alpha-actin staining cells with
the ultrastructural appearance of myofibroblasts appear in
the adventitia by 4 to 10 days and repopulate the neointima
by 4 weeks.21 Our immunohistochemical analysis revealed
that MCP-1 expression was reduced significantly in the E5
group at 2 and 4 weeks after surgery, when serum E2 levels
were elevated. At 4 weeks, the greatest reduction in MCP-1
staining occurred in the neointima and media/adventitia
adjacent to the IEL in regions populated with myofibro-
blasts. Reduction in MCP-1 correlated with decreased mac-
rophage accumulation. At 2 weeks, the reduction in
MCP-1 staining seen transmurally in the E5 group is likely
secondary to decreased macrophage infiltration and prolif-
eration. Furthermore, our MCP-1 message analysis showed
MCP-1 mRNA expression had a tendency of attenuation at
2 weeks and was reduced significantly at 4 weeks in the E5
group compared to the PL group, although there was no
difference between the two groups at 8 weeks after serum
E2 levels returned to baseline. These results were consistent
with our immunohistochemistry results. Finally, when a
comparison was made between serum E2 levels at harvest of
the graft and the percentage of cells in that graft staining
positive for ED1, PCNA, or MCP-1, a negative Spearman
correlation coefficient was obtained, indicating that ele-
vated levels of serum E2 were correlated with lower levels of
these indicators of IH.
How E2 affects MCP-1 expression is unclear and the
focus of future experiments. Estrogen receptor expression
has been demonstrated by VSMCs and endothelial
cells.23,24 Yue and colleagues25 reported that the estrogen
receptor modulator, idoxifene, inhibited neointimal forma-
tion in a rat balloon arterial injury model by decreasing
VSMC proliferation. Kauffman et al26 demonstrated that
raloxifene, a second estrogen receptor modulator, also de-
creased intimal thickening following arterial injury. Kauff-
man et al reported that raloxifene’s beneficial effect was
blocked when treating their rats with a pure estrogen
receptor antagonist, ICI 182,780. However, pretreatment
with the receptor antagonist did not completely block the
reduction in intimal areas seen with E2 treatment. Thus it is
likely that estradiol’s effect on the vascular wall is in part
receptor–mediated but that other mechanisms indepen-
dent of estrogen receptors may be involved.
CONCLUSION
17-Estradiol inhibited vein graft IH coincident with a
reduction in the expression of MCP-1. Estradiol treatment
reduced cellular proliferation and decreased macrophage
infiltration of rat vein grafts. Future studies will be directed
toward determining the cell types and cell biology influ-
enced by estradiol. Our goal will be to gain sufficient
knowledge to determine whether the attenuation of IH by
estradiol or other estrogen receptor agonists can be made
permanent within an acceptable clinical safety profile.
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